Jim Cramer While Discussing Johnson & Johnson: “It’s Still Too Early to Buy the Momentum Stocks”

Johnson & Johnson (NYSE:JNJ) is one of the stocks that Jim Cramer recently commented on. Cramer discussed the stock in light of its latest quarter and analyst sentiment around it. He said:

“Sometimes you get these days where it feels like the market has returned to some semblance of what you’re used to when things get shaky. I mean, these are the days when J&J will reign supreme… My guess is that there’ll be maybe two or even maybe three days where interest rates are lower. This was day one, and you have to wait as the food and drug analysts come out from under the table and start bragging loudly about their flock and about how it’s time to buy. That’s what those guys always do… Which analysts are going to resist going out positive on J&J, which has moved up every day seemingly since the last quarter, maybe since they announced that quarter. Maybe the food analysts can talk up mergers… They’re reasonable presumptions, and they’ll preclude a serious tech rally or a speculative surge. Hear what I said, preclude. It’s still too early to buy the momentum stocks.”

Jim Cramer While Discussing Johnson & Johnson: "It’s Still Too Early to Buy the Momentum Stocks”

Trong Nguyen / Shutterstock.com

Johnson & Johnson (NYSE:JNJ) develops and sells a wide range of healthcare products, including prescription treatments for major diseases and advanced medical technologies.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.